Anales de la RANM

27 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 SOBRECARGA DE HIERRO. ¿POR QUÉ TRATAR? Ana Villegas Martínez Año 2018 · número 135 (01) · páginas 20 a 27 a prospective study usin T2* cardiovascular mag- netic resonance. Br. J. Haematol 2004; 127: 348- 355. 25. St Pierre TG, Clark PA, Chua-Anusen W et al. Non invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-861. 26. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Sing S. Kinetics of removal and reapareance of non-transferrin bound plasma iron with deferoxa- mine therapy. Blood 1996; 88: 705-713. 27. Wood JC. Guidelines for quantifying iron over- load. Hematology Am. Soc Hematol Educ Program 2014(1): 210-215. 28. Pennell DJ, Porter JB, Piga A et al. Sustained im- provements in myocardial T2* over 2 years in seve- rely iron ever loaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol 2015; 90(2): 91-96. 29. Westwood MA, Firmin DN, Gildo M et al. Inter- centre reproductibility of magnetic resonance T2* measurements of myocardial iron thalassemia. Int J Cardiovasc Imaging 2005; 21: 531-538. 30. Pennell DJ, Porter JB, Piga A et al. A 1 year rando- mized controlled trial of deferasirox vs desferroxa- mina for myocardial iron removal in beta thalas- semia major (CORDELIA). Blood 2014; 123(10): 1447-1454. 31. Porter JB, El-Alfy M, Viprasit V et al. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. Eur J Haematol 2016; 96(1): 19-26. 32. De Swart L, Hendriks JCM, Van der Vorm LN et al. Second international round robin for the quantifi- cation on of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload di- sorders. Hematologica 2016; 101(1): 38-45. 33. Malcovati L, Germing U, Kuendgen A et al. Time dependent pronostic scoring system for predicting survival and leukemia evolution in myelodysplastic syndromes. J. Clin Oncol 2007; 25: 3503-3510. 34. Remacha AF, Arrizabalaga B, Villegas A et al. Evo- lution of iron overload in patients with low-risk myelodysplastic syndrome iron chelation therapy and organ complications. Ann Hematol 2015; 94(5) 779-787. 35. Mainnous AG, Tanner RJ, Hulihan MM, Amaya M, Coates TD. The impact of chelation therapy on sur- vival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Br J Haematol 2014; 167(3): 720-723. 36. Angelucci E, Pilo F. Iron overload before, during and after hematopoietic stem cells transplantation. Prog Educ. EHA 22nd Congress. Madrid. June 2017 P.5. 37. Taher AT, Origa R, Perrsotta S et al. New film- coated tablet formulation of deferasirox is well to- lerated in patients with thalassemia or lower-risk MDS: results of the randomized phase I ECLIPSE study. Am J Hematol 2017. doi 10.1002/ajh 24 668. 38. Xia S, Zhang W, Huang L, Jiang H. Comparative efficary and safety of Deferoxamine, Deferiprone and Deferasirox on severe thalassemia. A meta- analysis of 16 Randomized Controlled Trials. Plos One 2013; 8(12) e 82662. 39. Malcovati L, Porta MG, Pascutto C et al. Prognos- tic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23(30): 7594-7603. 40. Cazzola M, Malcovati L. Myelodysplastic syndro- mes coping with ineffective hematopoiesis. N Engl J Med 2005; 352: 536-538. 41. Rose C, Brechignac S, Vassillief D. Does iron chela- tion therapy improve survival in regularly transfu- sed lower risk MDS patients?. A multicenter study by GMF. Leuk Res 2010; 34(7): 864-870. 42. Lyons RM, Marek BJ, Paley C et al. Comparison of 24-month outcomes in chelated and no-chelated lower-risk patients with myelodysplastic syndro- mes in a prospective registry. Leuk Res 2014; 38(2): 149-154. 43. Arrizabalaga A, del Cañizo C, Remacha A, Sanz G, Villegas A. Guía de quelación del paciente con síndrome mielodisplásico. Haematologica 2008; 91(1): 3-10. 44. González FA, Arrizabalaga B, Villegas A et al. Estu- dio del tratamiento con deferoxamina en perfusión contínua subcutánea para la sobrecarga de hierro en pacientes con síndrome mielodisplásico. Med Clin 2005; 124: 641-644. 45. Angelucci E, Santini V, Di Tucci AA et al. Defe- rasirox for transfusion-dependent patients with myelodysplastic syndromes : safety, efficacy and beyond (GIMENA MDS 0306 Trial). Eur J Haema- tol 2014; 92(6): 527-536. 46. Breccia M, Voso MT, Aloe Spiriti MA et al. An increase in hemoglobin platelets and white bood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syn- dromes: clinical evidences and possible biological mechanisms. Ann Hematol 2015; 94(5): 771-777. 47. Lyons RM, Marek BJ, Paley C et al. Relation bet- ween chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leuk Res 2017; 56: 88-95. 48. Butter A, Patton WN. Iron chelation therapy in myelodysplastic syndromes: we need more evi- dency, not more guidelines. Intern Med J 2012; 42: 481-484. 49. Armand P, Kim HT, Cutler CS et al. Prognostic im- pact of elevated pretransplatation serum ferritin in patients undergoing myeloablative stem cell trans- plantation. Blood 2007; 109: 4586-4588. 50. Tefferi A. Iron overload and stem cell transplant and the beat goes on. Am J Hematol 2011; 86: 825- 826. Si desea citar nuestro artículo: Villegas-Martínez A. Sobrecarga de Hierro. ¿Por qué tratar? ANALES RANM [Internet]. Real Academia Nacional de Medicina de España; 2018 Sep 3; 135(01):20–27. DOI: http://dx.doi.org/10.32440/ar.2018.135.01.rev03